简介:Pre-mRNAsplicingisafundamentalprocessrequiredfortheexpressionofmostmetazoangenes.Itiscarriedoutbythespliceosomethatcatalyzestheremovalofnon-codingintronsequencestoligateexonsintomaturemRNApriortotransportandtranslation.Thepurposeofourstudyistoexplorewhethertheinvitrounlabeledpre-mRNAsplicingassaycouldbeperformedasanalternativemethodofsplicingreactionotherthantheradiolabeledone.Twodifferentsplicingmethodsinvitro,Plabeledandunlabeledpre-mRNAasthesubstratesinthereaction,wereinvestigated.TheradiolabeledproductswerevisualizedbyautoradiographywhiletheunlabeledproductswereobservedbyEthidiumBromide(EB)staining.Asaresult,althoughtherearemoreunspecificbandsintheEBstainingassaythan32Plabeledone,theRNAproductsofinvitrosplicingcouldbeobservedclearly.Thissuggeststhattheunlabeledpre-mRNAsplicingassaycanbeanoptionalsubstitutionfortheisotope-labeledassay.
简介:摘要目的探讨ATP7B基因罕见同义变异对其前体mRNA剪接的影响。方法从ExAc数据库中筛选出人群等位基因频率<0.005的248种罕见同义变异,用Human Splicing Finder(HSF)软件分析其对于前体mRNA剪接的影响,进一步用ESE Finder 3.0软件预测其对于反式作用因子SR蛋白家族结合能力的影响。筛选出同时影响两种或以上SR蛋白结合的罕见同义变异,用体外迷你基因剪接报告系统进行验证。结果HSF分析提示有136种罕见同义变异可能破坏外显子剪接增强子(exonic splicing enhancer,ESE)的基序;ESE Finder 3.0分析提示其中19种会同时影响两种或以上SR蛋白的结合。体外迷你基因实验证实其中c.1620C>T(p.L540L)和c.3888C>T(p.A1296A)变异可导致相应外显子的剪接异常,分别造成第4外显子的完全跳跃以及使第18外显子的跳跃增加25%。结论同义变异可能通过各种途径影响前体mRNA的剪接,其中以破坏ESEs基序最为常见。本研究结果证实c.1620C>T(p.L540L)和c.3888C>T(p.A1296A)变异会对ATP7B基因的mRNA剪接产生影响,使相应的外显子发生跳跃,从而为携带者的基因诊断和遗传咨询提供了依据。
简介:摘要目的探讨可变剪接事件结合剪接因子对乳头状肾细胞癌患者预后的预测作用。方法从TCGA数据库下载乳头状肾细胞癌患者的临床相关资料(性别、年龄、分期等)及转录组数据,并从TCGASpliceSeq数据库获得可变剪接事件信息。通过R语言软件及程序包,使用LASSO、Cox回归模型筛选相关可变剪接事件及相关特异剪接因子,建立乳头状肾细胞癌预后模型,进行独立预后分析,并绘制剪接事件相关的调控网络。结果通过单因素Cox比例风险回归模型确定1 405个可变剪接事件与乳头状肾细胞癌相关,包括可变受体位点(AA)事件98个、可变供体位点(AD)事件101个、可变启动子(AP)事件333个、可变终止子(AT)事件346个、外显子跳跃(ES)事件448个、外显子互斥(ME)事件3个和内含子保留(RI)事件76个。经过LASSO、多因素Cox比例风险回归分析,并结合临床数据,显示可变剪接事件(C16orf13|32924|ES、TSFM|22759|ES、MACF1|1881|ES、ATP5C1|10726|ES、UNG|24277|AP、UNKL|33077|AP)可能是乳头状肾细胞癌的独立预后风险因素(HR=1.028,95%CI:1.018~1.039,P<0.01)。通过相关性分析寻找乳头状肾细胞癌中可变剪接事件与剪接因子之间的潜在调控关系,构建调控网络,共116个剪接因子及1 059个可变剪接事件纳入分析,其中正、负相关调控事件分别为553、506个。结论可变剪接事件结合相关临床数据对预测乳头状肾细胞癌患者预后具有一定意义,对探索乳头状肾细胞癌的研究具有重要作用。
简介:摘要目的分析一个X连锁显性遗传Alport综合征家系COL4A5基因的剪接突变位点,探索外显子特异性U1核小RNA(small nuclear RNA,snRNA)基因治疗的可能性。方法收集Alport综合征先证者及其家族成员临床资料,高通量测序技术检测先证者肾病系列基因全外显子组基因突变。用在线软件分析COL4A5 c.546+5G>A变异引起的剪接位点改变及其致病性。用minigene实验验证和分析Alport综合征家系先证者COL4A5基因突变位点c.546+5G>A及瞬时转染导入修饰过的U1 snRNA纠正剪接突变的效果。结果基因测序结果显示,先证者和其同母异父的兄长均存在COL4A5基因半合子变异,变异位点为c.546+5G>A。在线软件分析剪接变异致病性的结果显示,突变后原有的Donor剪切位点检测不到,提示影响剪切可能性很大。杂交小基因检测结果验证了COL4A5基因c.546+5G>A突变的异常剪接模式——外显子9缺失。经过修饰的U1 snRNA可部分纠正该异常的剪接突变,ExSpeU1(MT)、ExSpeU1(E9+1)、ExSpeU1(E9+9)、ExSpeU1(E9+11)对c.546+5G>A引发的外显子9缺失的纠正比例分别为0、43.81%、52.09%、48.12%。结论COL4A5新发剪接突变具有致病性,修饰过的U1 snRNA可部分纠正异常剪接。
简介:摘要目的探讨可变剪接事件及剪接因子对雄激素剥夺疗法(ADT)治疗的前列腺癌患者预后的预测作用。方法从TCGA数据库下载60例进行ADT治疗的前列腺癌患者相关临床、转录组信息,并获得可变剪接事件信息。通过R语言程序包,使用LASSO、Cox回归模型筛选相关可变剪接事件及剪接因子,建立相关模型,进行独立预后分析及相关调控网络分析。结果确定前列腺癌患者相关可变剪接事件44 070个,包含可变受体位点(AA)3 525个、可变供体位点(AD)3 101个、可变启动子(AP)9 035个、可变终止子(AT)8 663个、外显子跳跃(ES)16 772个、外显子互斥(ME)228个和内含子保留(RI)2 747个。通过单因素Cox比例风险回归模型确定1 349个可变剪接事件为与ADT相关的疾病进展相关剪接事件(DFS-SE),包括AA事件145个、AD事件102个、AP事件243个、AT事件189个、ES事件557个、ME事件6个和RI事件107个。多因素Cox回归分析显示,加入临床相关信息后,ME事件(ANK3|11852|ME、TCF7L2|151705|ME、UBR2|127390|ME、SLC39A14|140283|ME)可能为预测ADT抵抗的独立预后因子(HR=1.398,95% CI 1.156~1.689,P<0.01)。结论ME类可变剪接事件结合相关临床数据对预测前列腺癌患者ADT有效性具有一定意义,对探索前列腺癌患者ADT抵抗的研究具有重要作用。
简介:Thepurposeofthestudyistoestablishafluorescencequantitativereversetranscriptionpoly-merasechainresponse(FQ-RT-PCR)methodforthequantitativedeterminationofIL-2mRNAandIL-4mRNAinThcells,withwhichtheThcellsstatusofthepatientswithgynaecologicaltumorsandchronicrenalfailure(CRF)canbeanalyzed.IL-2cDNAandIL-4cDNAwereprepared,andtheplasmidpMD18carryingIL-2cDNAorIL-4cDNAfragmentwasconstructedandclonedasthetemplateforquantitativedetermination.Theprimersandprobeslabelledwith6-carboxy-fluorescein(FAM)and6-carboxy-tetrarnethylrhodamine(TAMRA)wereprepared,andtheexperimentalconditionswereoptimizedtosetuptheFQ-RT-PCRmethodforquantitativedeterminationofIL-2mRNAandEL-4mRNA.Thcellsenrichedfromperipheralbloodmononuclearcells(PBMCs)of20healthyvolunteers(HVs),16gynaecologicalbenign(GB)cases,18gynaecologicalmalignant(GM)tumorcasesand16chronicrenalfailure(CRF)patientsweretestedforIL-2mRNAandIL-4mRNAbyFQ-RT-PCR.Thehouse-keepinggeneβ-actinwasusedastheinternalcontrolgeneoftheexperiment.Thestandardcurveforlogconcentrationofseriesofquantitativetemplatesvsthresholdcycle(CT)wasestablishedbylinearregression,andthelinearrangewas102-107copies/μl.TheimprecisiontestshowedtheCVofinter-assayandintra-assayofahighcontentsamplebyFQ-RT-PCRwere7.8%and12.5%,respectively.TheCVofinter-assayandintra-assayofalowcontentsamplewere10.8%and19.5%,respectively.TheIL-2mRNAexpressionsinThofthepatientswithgynaecologicalmalignanttumor(comparedwiththeHVsandthepatientswithgynaecologicalbenigndisease)andinThoftheCRFpatients(comparedwiththeHVs)weredeclinedsignificantlyandatthesametimetheIL-4mRNAexpressionincreasedsignificantly(P<0.001).Asimple,sensitiveandaccurateFQ-RT-PCRmethodforthequantitativedetectionofIL-2mRNAandIL-4mRNAhasbeenestablished.TheIL-2mRNAandIL-4m
简介:AbstractThe first practice of pre-implantation genetic testing (PGT) was reported more than 30 years ago. PGT, originally named preimplantation genetic screening (PGS) and pre-implantation genetic diagnosis (PGD), is now categorized as PGT for aneuploidies (PGT-A), PGT for monogenic/single-gene defects (PGT-M), and PGT for chromosomal structural rearrangements (PGT-SR). Patients with fertility issues caused by advanced maternal age, carrier status of chromosomal abnormalities, or harboring pathogenic variant(s) are recommended to undergo PGT to increase the possibility of successful live birth and avoid potentially affected newborns. High-throughput techniques, such as DNA microarrays and next-generation sequencing (NGS), have enabled comprehensive screening of all 24 chromosomes, instead of few loci at a time. Furthermore, as a comprehensive PGT, PGT-Plus was enabled by the rapid development of a genome-wide single-cell haplotyping technique to detect embryo aneuploidy, single-gene disorders, and chromosomal aberrations simultaneously using a single universal protocol. In addition, non-invasive approaches enable a more intact embryo during the biopsy procedure, which may avoid potential mosaicism issues at a certain scale by testing spent culture media (SCM). As a novel PGT application, PGT-P detects genome-wide variations in polygenic diseases, which account for a large proportion of premature human deaths and affect a markedly larger population than monogenic diseases, using polygenic risk score calculation to decrease the potential of affecting complex conditions. Owing to the emergence of new technologies recruited to PGTs, more couples with infertility issues have a promising chance of conceiving a healthy baby, ultimately facilitating the human species to live more prosper.
简介:目的探讨乙型肝炎病毒pre—S1Ag、pre—S2Ag、HBV—DNA、HBV—M的相关性及其临床意义。方法HBV—DNA采用荧光定量PCR法;HBV—M及pre—S1Ag、pre—S2Ag采用ELISA法,检测96例HBV—DNA阳性感染者血清中pre-S1Ag、pre—S2Ag、HBV—M,同时以30例HBV—M全阴性的健康体检者血清作为对照,并对结果进行统计学分析。结果96例HBV—DNA阳性患者中HBsAg、HBeAg、HBcAb阳性检出率为64.6%;HBsAg、HBeAb、HBcAb阳性检出率为20.8%;HBsAg、HBcAb阳性栓出率为14.6%;pre—S1Ag在96例HBV—DNA阳性标本中检出率为70.8%;pre—S2Ag检出率为79.2%;均明显高于HBeAg的阳性率64.6%,30例对照中未检测出pre—S1Ag、pre—S2Ag及HBV—DNA。结论HBeAg、HBV—DNA、pre—S1Ag、pre—S2Ag之间具有一定的关联性。pre—S1Ag和pre—S2Ag均较HBeAg敏感。pre—S1Ag与pre—S2Ag的栓出率差异无显著性,ELISA检测HBV—M、pre—S2Ag及pre—S1Ag只是表型指标,只能提供HBV感染的间接证据。而HBV—DNA的检测是HBV感染与否的直接证据。HBV—M、pre—S1Ag、pre—S2Ag、HBV—DNA的检测各自有其独特的临床意义。应用pre—S1Ag、pre—S2Ag、HBV—DNA及HBV—M进行联合检测,对HBV感染的早期诊断,了解HBV复制、转归及监测疗效和预后有重要的意义。
简介:Gapinducedpie-pulseinhibition(Gap-PPI)ofacousticstartlereflexhasbeenusedasameasurementoftinnitusinanimalmodels.However,whetherthistestissensitivetodetecttinnitusinhumansisstillunclear.Basedonthetestingprocedureusedinanimalstudies,ahumansubjecttestingmethodwasformulatedandconductedtoinvestigateifasimilarresultcouldbefoundintinnituspatients.Audiologicandtinnitusassessmentsandacousticstartlereflexmeasurementswereperformedonseventinnitussubjectsandnineagematchedsubjectswithouttinnitus.TherewasnosignificantdifferencefoundbetweenthecontrolandtinnitusgroupontheGap-PPlacrossthefrequenciesevaluated.Theamplitudeofthestartleresponseinthetinnitusgroupwithnormalhearingthresholdswassignificantlyhigherthanthecontrolgroupandthosewithtinnitusandhearingloss.Thispreliminaryresultsuggeststhathyperexcitabilityinthecentralauditorysystemmaybeinvolvedintinnitus.Therewasnocorrelationbetweenhearingthresholdsandtheincreasedamplitudeofstartleresponse.
简介:Objective:Toreportasurgicalmethodforthetreatmentofpre-auricularfistulatolowerpost-operativerecurrencerate.Methods:Clinicaldataof187patientswithpre-auricularfistulawhounderwentenblocresectionattheAffiliatedHospitalofLuzhouMedicalCollegefromAugust2006toNovember2012wereretrospectivelyreviewed.FactorsthatmightaffecttheprognosisfollowingEnblocfistularesectionborderedbythesuperficialtemporalisfascia,helixperichondriumandauriculocephalicsulcuswereinvestigated.Results:Ofthe187patients,181achievedprimaryhealingand6endedupwithdelayedhealing.Duringthefollow-upperiod(onetosevenyears),therewere4casesofrecurrence(2.1%).Conclusions:Cleardemarcationofsurgicalresectioncanfacilitateeasyandthoroughresectionofpreauricularfistulaandleadtolowrecurrencerate.Propertimingandcarefulsearchforpotentialfistulabranchesarethetwocrucialfactorsaffectingprognosis.
简介:摘要信使RNA(messenger RNA, mRNA)疫苗属于第三代疫苗,即核酸疫苗,具有细胞内表达速度快、有效性和安全性高、反应速度快、易规模化扩大和高成本效益比等特点,在近30年中取得了突飞猛进的发展,越来越多的证据表明可以用合理的方法来提高这类现代疫苗的有效性和安全性。2020年暴发的由新型冠状病毒引起的新型冠状病毒肺炎大流行给全世界带来了巨大的灾难,导致了过亿例感染和数百万例死亡,疫苗被认为是阻断传播和控制疾病的唯一希望。在所有的疫苗种类中,mRNA疫苗极快的研发速度和有效性引起了广泛的关注。此综述就mRNA疫苗的体内摄取和抗原表达、固有免疫的作用、适应性免疫的激活、mRNA疫苗递送系统以及注射途径的效应等角度进行阐述,以期为mRNA疫苗的设计提供有价值的参考。
简介:无
简介:摘要目的对2例中国汉族成骨不全症(osteogenesis imperfecta,OI)患者进行突变检测,对其候选剪接变异进行致病性鉴定。方法采用常规酚-氯仿法从2例中国汉族OI先证者的外周血中提取基因组DNA,通过全外显子组测序(WES)进行致病突变筛查;针对检出的可能引起RNA剪接异常的疑似致病变异,构建Minigene分析变异对于剪接的影响,进而确定其致病性。结果在先证者1中发现可能影响剪接的杂合变异:COL1A1:c.858+1_858+5delGTAAG;先证者2同时存在COL1A2的两个变异,一个为可能引起异常剪接的杂合变异c.1405-7C>T,另一个为杂合错义变异c.2972G>T(p.G991V)。Minigene实验分析证实家系1的变异导致COL1A1基因第12外显子发生跳跃,家系2变异位点c.1405-7C>T对COL1A2的转录后剪接没有影响。先证者2的COL1A2基因的G991为一个高度保守的氨基酸,经生物信息学分析c.2972G>T(p.G991V)可能为真正的OI致病变异。结论先证者1的COL1A1剪接位点变异c.858+1_858+5delGTAAG是导致OI的致病性变异;排除先证者2中COL1A2变异c.1405-7C>T的致病性,确定COL1A2基因变异c.2972G>T(p.G991V)为先证者2的致病原因。针对WES提示的剪接变异进行Minigene分析,不仅实现了突变致病性鉴定,丰富了OI的突变谱,而且为患者产前诊断和后续机制研究奠定了基础。
简介:摘要目的探讨与肝纤维化相关差异表达mRNA在发病机制中的作用。方法1构建胆汁淤积性肝纤维化化动物模型,分为胆管结扎模型组、只开腹不结扎对照组以及胆管结扎并且赖氨大黄酸(RHL)治疗的赖氨大黄酸组。2应用芯片技术分别检测模型组组与对照差异表达的mRNA、赖氨大黄酸组与模型组差异表达的mRNA。3对差异表达mRNA进行整合分析,确定对肝纤维化有影响的差异表达的mRNA。4应用MoleculeAnnotationSystem(MAS)软件对差异表达mRNA进行GO和KEGG分析。结果1模型组与对照组相比,635个基因表达上调,366个基因表达下;赖氨大黄酸组与模型组相比,59个基因表达上调,43个基因表达下调。2重合分析共43个差异表达的mRNA。3GO分析显示43个差异表达的mRNA主要在细胞质和细胞器参与结合、分子调节器、代谢调节过程等功能。4KEGG分析显示43个差异表达的mRNA主要PPAR信号通路、代谢途径、脂肪细胞因子信号通路等信号传导通路。结论差异表达的mRNA可能影响肝纤维化进程。